Current status of selective estrogen receptor modulators (SERMs).
Conzen
Suzanne D
SD
Department of Medicine and Committee on Cancer Biology, University of Chicago, Chicago, Illinois 60637, USA.
D001578:Benzopyrans / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology; D020847:Estrogen Receptor Modulators / Q000494:pharmacology; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology; D015394:Molecular Structure; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology; D020845:Selective Estrogen Receptor Modulators / Q000737:chemistry / Q000494:pharmacology*; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000494:pharmacology; D013876:Thiophenes / Q000737:chemistry / Q000494:pharmacology
C439584:2-(4-hydroxyphenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-1H-indol-5-ol; D001578:Benzopyrans; D004965:Estrogen Antagonists; D020847:Estrogen Receptor Modulators; D007211:Indoles; D010880:Piperidines; D011422:Propionates; D020845:Selective Estrogen Receptor Modulators; D013876:Thiophenes; D013629:Tamoxifen; D000077267:Fulvestrant; D004958:Estradiol; C115121:LY 353381; C106945:EM 800